Endokrynologia PolskaPub Date : 2024-01-01Epub Date: 2024-04-22DOI: 10.5603/ep.98240
Agata Czarnywojtek, Paweł Gut, Kamil Dyrka, Jerzy Sowiński, Nadia Sawicka-Gutaj, Katarzyna Katulska, Piotr Stajgis, Mateusz Wykrętowicz, Jakub Moskal, Jeremi Kościński, Krzysztof Pietrończyk, Patryk Graczyk, Maciej Robert Krawczyński, Ewa Florek, Ewelina Szczepanek-Parulska, Marek Ruchała, Alfio Ferlito
{"title":"Standard therapy or additionally radioactive iodine (131I) therapy; which will stop the recurrence of glioblastoma multiforme (GBM)?","authors":"Agata Czarnywojtek, Paweł Gut, Kamil Dyrka, Jerzy Sowiński, Nadia Sawicka-Gutaj, Katarzyna Katulska, Piotr Stajgis, Mateusz Wykrętowicz, Jakub Moskal, Jeremi Kościński, Krzysztof Pietrończyk, Patryk Graczyk, Maciej Robert Krawczyński, Ewa Florek, Ewelina Szczepanek-Parulska, Marek Ruchała, Alfio Ferlito","doi":"10.5603/ep.98240","DOIUrl":"10.5603/ep.98240","url":null,"abstract":"<p><p>Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumour. The average survival time for a patient diagnosed with GBM, using standard treatment methods, is several months. Authors of the article pose a direct question: Is it possible to treat GBM solely with radioactive iodine (¹³¹I) therapy without employing the sodium iodide symporter (NIS) gene? After all, NIS has been detected not only in the thyroid but also in various tumours. The main author of this article (A.C.), with the assistance of her colleagues (physicians and pharmacologists), underwent ¹³¹I therapy after prior iodine inhibition, resulting in approximately 30% reduction in tumour size as revealed by magnetic resonance imaging (MRI). Classical therapy for GBM encompasses neurosurgery, conventional radiotherapy, and chemotherapy (e.g. temozolomide). Currently, tyrosine kinase inhibitors (imatinib, sunitinib, and sorafenib) are being used. Additionally, novel drugs such as crizotinib, entrectinib, or larotrectinib are being applied. Recently, personalised multimodal immunotherapy (IMI) based on anti-tumour vaccines derived from oncolytic viruses has been developed, concomitant with the advancement of cellular and molecular immunology. Thus, ¹³¹I therapy has been successfully employed for the first time in the case of GBM recurrence.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"75 2","pages":"130-139"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endokrynologia PolskaPub Date : 2024-01-01Epub Date: 2024-06-18DOI: 10.5603/ep.99050
Busra Tunc Topuz, Sibel Guldiken, Ebru Tastekin, Canberk Topuz, Mehmet Celik, Buket Yılmaz Bulbul, Burak Andac, Ali Cem Yekdes
{"title":"The association between integrin β4 overexpression and lymphovascular invasion in papillary thyroid cancer.","authors":"Busra Tunc Topuz, Sibel Guldiken, Ebru Tastekin, Canberk Topuz, Mehmet Celik, Buket Yılmaz Bulbul, Burak Andac, Ali Cem Yekdes","doi":"10.5603/ep.99050","DOIUrl":"10.5603/ep.99050","url":null,"abstract":"<p><strong>Introduction: </strong>Lymphovascular invasion is an independent prognostic marker in papillary thyroid carcinomas. In addition, integrin β4 is associated with advanced progression and metastasis in many malignancies. We aimed to investigate the relationship between integrin β4 and lymphovascular invasion in papillary thyroid carcinoma.</p><p><strong>Material and methods: </strong>73 patients with papillary thyroid cancer (48 patients with lymphovascular invasion and 25 patients without) were included in our study. The immunohistochemical staining score for integrin b4 was evaluated according to the percentage and intensity of staining. The staining intensity was scored as 0 (no staining), 1 (weak staining - light yellow), 2 (medium staining - yellow-brown), and 3 (strong staining - brown). The staining was scored by multiplying the percentage and intensity of staining.</p><p><strong>Results: </strong>The mean percentage of integrin b4 staining was 63.54 ± 22.26% in the group with lymphovascular invasion and 10.2 ± 22.48% in the group without lymphovascular invasion (p < 0.001). When evaluated in terms of staining score, it was found to be 107.08 ± 45.29 in the group with lymphovascular invasion and 16.2 ± 40.03 in the group without lymphovascular invasion (p < 0.001). There was a linear relationship between the percentage of integrin β4 and the staining scores (r² = 0.881; p < 0.001). In the by receiver-operating characteristic (ROC) curve analysis for the cut-off value of the percentage of integrin b4 staining, the area under the curve was found to be 0.916. The cut-off value for the percentage of integrin b4 was found to be 35 (sensitivity 91.7% and specificity 88%) (odds 80.66%).</p><p><strong>Conclusions: </strong>A significant relationship was found between integrin b4 expression and lymphovascular invasion in papillary thyroid carcinomas. Integrin b4 expression level can be used as a marker to predict the presence of lymphovascular invasion in papillary thyroid carcinomas, especially in large tumours where it may not be possible to sample the entire tumour.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"310-316"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paula Nowocień, Dominika Rokicka, Marta Wróbel, Artur Gołaś, Sonia Rokicka, Dorota Stołtny, Dariusz Kajdaniuk, Bogdan Marek, Krzysztof Strojek
{"title":"Training under normoxia and normobaric hypoxia in patients with type 1 diabetes","authors":"Paula Nowocień, Dominika Rokicka, Marta Wróbel, Artur Gołaś, Sonia Rokicka, Dorota Stołtny, Dariusz Kajdaniuk, Bogdan Marek, Krzysztof Strojek","doi":"10.5603/ep.99346","DOIUrl":"10.5603/ep.99346","url":null,"abstract":"<p><p>Apart from insulin, physical exercise is a crucial component of therapy in patients with type 1 diabetes mellitus (T1DM). The benefits of physical activity in such patients include improved insulin sensitivity, lowered blood glucose, reduced body fat and improved cardiovascular function and physical performance. Hypoglycemia is a crucial issue in the peri-training period in insulin-treated patients. Proper preparation for exercise is the key to reducing the risk of hypoglycemia. The selection of the training type and the patient's knowledge of the effect of such training on glycemia are also significant. Physical exercise under normobaric hypoxia in the training rooms is also available commercially and is becoming increasingly popular. Under such conditions, the air consists of 15.4% oxygen and 84.5% nitrogen, which corresponds to the conditions at an altitude of approximately 2,500 meters above sea level. Hypoxia induces the production of the hypoxia-inducible factor (HIF-1), which regulates the expression of over 100 genes. It modulates key metabolic pathways to optimize glucose utilization by increasing cell sensitivity to insulin, more efficient glucose uptake from the blood and activating effect on glycolytic enzymes. Additionally, HIF-1 shows beneficial effects on the lipid profile, vascular endothelium and performance as measured by the maximal oxygen uptake (VO2max). The aim of this paper was to review and summarize the most recent studies on the effects of exercise on glycemic control and physical performance under normoxia and normobaric hypoxia in patients with T1DM.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"75 4","pages":"403-411"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endokrynologia PolskaPub Date : 2024-01-01Epub Date: 2024-05-06DOI: 10.5603/ep.99376
Mateusz Klimek, Martyna Fecko, Tomasz Zieliński, Henryk Koziołek, Jacek Gawrychowski, Mirosława Mackiewicz, Krzysztof Nowosielski
{"title":"Acute pancreatitis associated with primary hyperparathyroidism during pregnancy.","authors":"Mateusz Klimek, Martyna Fecko, Tomasz Zieliński, Henryk Koziołek, Jacek Gawrychowski, Mirosława Mackiewicz, Krzysztof Nowosielski","doi":"10.5603/ep.99376","DOIUrl":"10.5603/ep.99376","url":null,"abstract":"<p><p>Not required for Clinical Vignette.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"334-335"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endokrynologia PolskaPub Date : 2024-01-01Epub Date: 2024-10-08DOI: 10.5603/ep.99456
Shuai Xu, Xinyi Zheng, Haibin Wu, Xujun You, Junwei Wu, Hai Zhou, Junhua Wu, Qianqian Liu, Ren-Qun Ye
{"title":"Feasibility study of lncRNA DHRS4-AS1 sponge miR-222-3p in the diagnosis of thyroid cancer.","authors":"Shuai Xu, Xinyi Zheng, Haibin Wu, Xujun You, Junwei Wu, Hai Zhou, Junhua Wu, Qianqian Liu, Ren-Qun Ye","doi":"10.5603/ep.99456","DOIUrl":"10.5603/ep.99456","url":null,"abstract":"<p><strong>Introduction: </strong>Thyroid cancer is a commonly occurring malignant tumour within the endocrine system, the incidence of which has been increasing steadily in our country. It has been the focus and direction of research in recent decades to continuously explore the diagnostic markers and molecular mechanisms of thyroid cancer and provide new possibilities for the healing of patients. In this study, lncRNA DHRS4-AS1 was identified as the research target, and the regulatory function of abnormal expression of DHRS4-AS1 on thyroid cancer was discussed.</p><p><strong>Material and methods: </strong>Thyroid cancer (116) and non-cancer normal (82) tissue samples were collected in this paper, and the expression of DHRS4-AS1 and miR-222-3p in tissues and cells were evaluated by RT-qPCR. CCK-8 and flow cytometry were used to detect cell survival status. The mechanism of DHRS4-AS1 sponge miR-222-3p was analysed by dual-luciferase reporter gene detection.</p><p><strong>Results: </strong>In the present study, DHRS4-AS1 was down-regulated in both thyroid tissue and cell samples, while miR-222-3p expression was elevated. The ROC curve reflected the diagnostic value of DHRS4-AS1 in thyroid cancer [area under the curve (AUC) = 0.887, sensitivity = 76.7%, specificity = 95.1%]. DHRS4-AS1 regulates the development of thyroid cancer by targeting miR-222-3p. In addition, in vitro experiments demonstrated that overexpression of DHRS4-AS1 (pcDNA3.1-DHRS4-AS1) inhibited the proliferation of thyroid cancer cells and promoted cell apoptosis, while down-regulating the level of miR-222-3p.</p><p><strong>Conclusions: </strong>DHRS4-AS1 acts as a miR-222-3p sponge in thyroid cancer, and overexpression of DHRS4 AS1 down-regulates cell proliferation and promotes cell apoptosis. These findings demonstrate the potential of DHRS4-AS1 as a diagnostic factor for thyroid cancer.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"494-500"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142396265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endokrynologia PolskaPub Date : 2024-01-01Epub Date: 2024-06-26DOI: 10.5603/ep.99689
Szymon Suwała, Roman Junik
{"title":"Metabolic-associated fatty liver disease and the role of hormones in its aetiopathogenesis.","authors":"Szymon Suwała, Roman Junik","doi":"10.5603/ep.99689","DOIUrl":"10.5603/ep.99689","url":null,"abstract":"<p><p>Metabolic-associated fatty liver disease (MAFLD) is a newly coined term that links the presence of liver steatosis (characterised by the accumulation of lipids in at least 5% of liver cells) with a condition of overall systemic metabolic dysfunction. MAFLD impacts 24-36% of the global population. As per the official guidelines, a diagnosis of MAFLD can be made when hepatosteatosis is accompanied by type 2 diabetes mellitus, overweight, obesity, or at least 2 other specific metabolic abnormalities (increased waist circumference, hypertension, dyslipidaemia, prediabetes, elevated C-reactive protein level, or increased homeostasis model assessment of insulin resistance: HOMA-IR). MAFLD is a heterogeneous illness associated with multiple diseases that impact various organs, particularly endocrine organs. Endocrinopathies can significantly influence the progression and severity of MAFLD. This paper provides a brief overview of the existing research on the connection between liver steatosis and the functioning of endocrine organs. The authors also propose dividing endocrine diseases into those having a possible, strong, and clear relationship with hepatosteatosis (for the purpose of preliminary recommendations regarding the need for monitoring the possible progression of MAFLD in these groups of patients).</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"237-252"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endokrynologia PolskaPub Date : 2024-01-01Epub Date: 2024-06-26DOI: 10.5603/ep.99199
Arnika Wydra, Jakub Wydra, Joanna Gątarek, Wojciech Zgliczyński, Izabella Czajka-Oraniec
{"title":"A remission of Cushing's disease after pituitary tumour apoplexy.","authors":"Arnika Wydra, Jakub Wydra, Joanna Gątarek, Wojciech Zgliczyński, Izabella Czajka-Oraniec","doi":"10.5603/ep.99199","DOIUrl":"10.5603/ep.99199","url":null,"abstract":"<p><p>Not required in Clinical Vignettes.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"32-329"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}